ARCH, one of life sciences' premier investors, eyes $3B for 13th fund

02 Feb 2024

ARCH Venture Partners plans to raise $3 billion for its 13th fund, per a new SEC filing from this week. The Chicago-based venture capital firm has been one of the most high-profile backers of life sciences companies for the past few decades and is behind many big names like Illumina, Altos Labs and Vir Biotechnology, among dozens of others. The firm was the fourth most active investor in private financings last year, per a recent report from investment bank William Blair, having taken part in 18 rounds in 2023. OrbiMed, which unveiled $4.3 billion across three new funds last fall, took first with 24 rounds. Flagship Pioneering, the investor and biotech creator behind the likes of Moderna, is also seeking $3 billion for its next fund, per an SEC filing last November.

For more details,please visit the original website

The content of the article does not represent any opinions of Synapse and its affiliated companies. If there is any copyright infringement or error, please contact us, and we will deal with it within 24 hours.

Organizations

Applied Research for Connected Health

Illumina, Inc.

Altos Labs, Inc.

[+3]

Indications

Targets

Drugs

Chat with Hiro

Hot reports

GPRC5D Target Patent Research Report

Patsnap Synapse

Global Drug R&D Express (July 2024)

PatSnap Synapse

siRNA Drug Amvuttra Patent Research and Practical Operation Guide

Patsnap Synapse

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Start your data trial now!

Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.